**Warfarin**

**Section:** 10. Medicines affecting the blood  >  10.2. Medicines affecting coagulation

### Indication
Cerebral ischaemic stroke due to embolic occlusion  
**ICD11 code:** 8B11.2

### INN
Warfarin

### Medicine type
Chemical agent

### List type
- Core (EML)
- Complementary (EMLc)

### Formulations
Oral > Solid: 5 mg (sodium salt); 1 mg (sodium salt); 2 mg (sodium salt); 0.5 mg (sodium salt) (EMLc)

### EML status history
- First added in 1977 (TRS 615)
- Changed in 1979 (TRS 641)
- Changed in 1982 (TRS 685)
- Changed in 1987 (TRS 770)
- Changed in 2007 (TRS 950)
- Changed in 2021

### Sex
All

### Age
Also recommended for children

### Therapeutic alternatives
Medicines within the same pharmacological class can be used

### Therapeutic alternatives limitations
Therapeutic alternatives to be reviewed (2023)

### Therapeutic alternatives limitations for EMLc
Therapeutic alternatives to be reviewed (2023)

### Patent information
Patents have expired in most jurisdictions  
Read more about patents.

### Wikipedia
Warfarin

### DrugBank
Warfarin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for warfarin be reviewed.